Gilead’s Darusentan, A Potential Blockbuster, Posts Positive Phase III Data
This article was originally published in The Pink Sheet Daily
Executive Summary
Analysts pleasantly surprised at both efficacy and safety data for the novel candidate as add-on treatment for resistant hypertension.
You may also be interested in...
Gilead President Thinks Firm Is Safe From Pfizer/GSK HIV Joint Venture - For Now
Near term, Gilead’s Milligan doesn’t see “anything really competitive.”
Gilead President Thinks Firm Is Safe From Pfizer/GSK HIV Joint Venture - For Now
Near term, Gilead’s Milligan doesn’t see “anything really competitive.”
Thrust & Parry: CVT And Gilead Look To Lock Out Astellas With Planned Merger
Gilead’s surprise $20 per share bid tops Astellas’ $16 per share offer, highlights Gilead’s increasing focus on cardiovascular space.